Why the MGC Pharmaceuticals (ASX:MXC) share price is leaping 5%

MGC Pharma shares are talking the talk today after a key update. Here's what we know.

| More on:
A group of science or medical professionals cheering good news in the lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is clicking higher on Thursday and is currently trading at 6.1 cents.

MGC shares are lifting after the company announced updates to its new production and supply agreement out of the United States.

For context, the S&P/ASX Health Care Index (ASX: XHJ) is currently only 0.5% higher so far today.

Here's what we know.

MGC Pharmaceuticals share price jumps after initial order placed

The MGC Pharmaceuticals share price is surging 5.17% after the company advised its distribution partner, AMC Holdings Inc, has placed an initial order of 1,000 units for the company's CimetrA label.

The order is "on an expedited basis, in order to fast track the approval process for the medication to be distributed and sold" throughout the US.

AMC will ship the units to a pharmacy where they "will then be analysed in order to make comparisons with MGC Pharma's research lab in Slovenia".

This process is the first step in materialising the US Supply Agreement signed by MGC and AMC last month. Both parties are working towards starting clinical trials and meeting supply milestones in the US for CimetrA.

CimetrA is MCG's lead drug candidate, designed to treat viral infections that produce inflammatory complications.

These complications include heart inflammation, breathing difficulties, loss of consciousness and even death.

COVID-19 falls under this umbrella, and the company began enrolments in July for a Phase 3 trial to treat COVID patients admitted to hospital using CimetrA.

Today's release notes that AMC is now working closely with the University of Florida on the "immediate submission of CimetrA to [the University's] internal review board" due to surges in US COVID-19 case numbers.

Aside from this, MGC is working closely with its partners to commercialise its adjacent drug labels, CannEpil and CogniCann, as per the announcement.

Investors appear to have bought on the news, and are pushing the MGC Pharmaceuticals share price higher in midday trading.

What did management say?

Speaking on the announcement, MGC Pharma CEO Roby Zomer, said:

AMC are already making significant progress in propelling CimetrA™, CannEpil® and CogniCann® to Clinical Trial stage in the US and we are pleased that they have cemented relationships with these prestigious institutions for the continued research into our products.

MGC Pharmaceuticals share price snapshot

The MGC Pharmaceuticals share price has rallied by around 144% this year to date and climbed by almost 9% this past month.

Over the last 12 months, MGC Pharma shareholders have enjoyed a return of 165%, ahead of the S&P/ASX 200 index (ASX: XJO)'s gain of about 25% in this time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.
Healthcare Shares

Buy the ASX 200 healthcare stock with 'decades of growth ahead'

This healthcare giant is well positioned for growth, experts say.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »